CytomX/$CTMX
1D1W1MYTD1Y5YMAX
About CytomX
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
- Ticker
- $CTMX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 69
- Headquarters
- South San Francisco, United States
- Website
- www.cytomx.com
CytomX Metrics
BasicAdvanced
$752M
-
-$0.45
2.14
-
Price and volume
Market cap
$752M
Beta
2.14
52-week high
$8.21
52-week low
$1.89
Average daily volume
2.8M
Financial strength
Current ratio
9.361
Quick ratio
9.264
Long term debt to equity
1.393
Total debt to equity
1.888
Profitability
EBITDA (TTM)
-86.211
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-435.19%
Operating margin (TTM)
-476.17%
Effective tax rate (TTM)
-0.29%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-19.58%
Return on equity (TTM)
-37.75%
Valuation
Price to revenue (TTM)
34.483
Price to book
2.49
Price to tangible book (TTM)
2.5
Price to free cash flow (TTM)
-7.652
Free cash flow yield (TTM)
-13.07%
Free cash flow per share (TTM)
-0.451
Growth
Revenue change (TTM)
-87.03%
Earnings per share change (TTM)
-193.01%
3-year revenue growth (CAGR)
-38.71%
10-year revenue growth (CAGR)
7.07%
3-year earnings per share growth (CAGR)
-10.84%
10-year earnings per share growth (CAGR)
-14.52%
What the Analysts think about CytomX
Analyst ratings (Buy, Hold, Sell) for CytomX stock.
CytomX Financial Performance
Revenues and expenses
CytomX Earnings Performance
Company profitability
CytomX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.